Fig. 4: In vivo CJ215 can detect ferroptosis in vivo for monitoring ferroptosis therapies or side effects of ferroptosis drugs. | npj Imaging

Fig. 4: In vivo CJ215 can detect ferroptosis in vivo for monitoring ferroptosis therapies or side effects of ferroptosis drugs.

From: Phosphatidylserine exposure and plasma membrane perforation as ferroptotic signatures for in vivo imaging

Fig. 4

a Scheme outlining the experimental workflow for ferroptosis imaging from the IKE injection to imaging and biodistribution studies done in Biorender. b Quantification of tumor uptake at 24 h after dye injection by subtracting the background CJ215 accumulation in each mouse across control, IKE treated and IKE+Liproxstatin treated groups. n = 5 mice. c Comparison of Contrast-to-Noise Ratio of CJ215 imaging in individual tumor-bearing mice treated with vehicle (control group), IKE and IKE+Liproxstatin imaged 24 h after dye injection. d Quantification of CJ215 fluorescence in different organs at 72 h after dye injection, indicating ferroptosis levels in mice groups treated with vehicle(control), IKE and IKE+Liproxstatin, indicating off-target effects of IKE treatment in inducing ferroptosis in specific organs, Mean ± s.d. p-values are reported over the lines (Ordinary one-way ANOVA with Tukey’s multiple comparisons). Scalebar 20 mm.

Back to article page